A Phase 1 interventional study of Apixaban in Venous Thromboembolism, sponsored by Bristol-Myers Squibb. Terminated at 14 sites in 5 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-04-07.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies testing apixaban in Venous Thromboembolism — 11 open to participants now, 11 under way, 1 of them phase 3. apixaban · Venous Thromboembolism.
Among the 37 studies testing apixaban in Venous Thromboembolism, this one is the 35th largest by enrollment, is the only one that started in 2011, is one of 5 in phase 1, and was the 1st registered.
713 studies on the registry are indexed under Venous Thromboembolism; 147 are open to participants now.
Browse Venous Thromboembolism studies →11 of the 37 studies testing apixaban in Venous Thromboembolism are open now, in 7 countries. Recruiting first, the newest first:
Military Hospital of Tunis · Sites in Tunisia
Ages 18–80
University of Vermont · Sites in United States
Ages 18+
Kiranya Arnold · Sites in United States
Ages 18–89
Rushad Patell · Sites in United States
Ages 18+
Medical University of Gdansk · Sites in Poland
Ages 18+
By country, each count listing its studies:
apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 113 Venous Thromboembolism studies recruiting now, 90 (80%) set no upper age limit and 13 (12%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.
This study: 12 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 6 · Phase 4 14
First in 2011; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 241 across 402 interventional studies indexed under Venous Thromboembolism.
Median enrollment 100 across the 37 interventional studies. Of the 25 that completed or were terminated, 12 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 37 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
12 studies in Venous Thromboembolism by Bristol-Myers Squibb: none open now, none under way, none of them phase 3. Of 12 finished, 1 (8%) have results posted.
Among the 12 studies in Venous Thromboembolism by Bristol-Myers Squibb, this one is one of 2 that started in 2011, is one of 2 in phase 1, and was the 1st registered.
Bristol-Myers Squibb’s Venous Thromboembolism studies by the year they started, since 2010.
7 of the studies testing apixaban in Venous Thromboembolism that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04874428Insel Gruppe AG, University Hospital BernDirect Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis | 2026-12 |
| NCT05683808University of Vermont Medical CenterVenous Thromboembolism Prevention in Outpatients With Glioma | 2026-12-30 |
| NCT07869615Military Hospital of TunisComparison of DOACs and LMWH for Thromboprophylaxis After Total Knee Arthroplasty | 2027-04-15 |
| NCT05735639Imperial College LondonTHRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE) | 2027-06-30 |
| NCT06886516Rushad PatellApixaban in Thrombocytopenia | 2027-07-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 37 studies testing apixaban in Venous Thromboembolism, from their registry updates:
Among Bristol-Myers Squibb’s 12 in Venous Thromboembolism:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
CV185-079 is a multiple dose Apixaban Pharmacokinetics/Pharmacodynamics (PK/PD) study in pediatric subjects. The objective of this study is primarily to study the PK/PD of Apixaban in pediatric subjects with a central venous catheter.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Group 5: 12 years to \<18 years; 0.66 mg/m² Oral solution, Oral, Twice A Day (BID), 10 days
Drug: Apixaban
Group 5: 12 years to \<18 years; 1.32 mg/m² Oral solution, Oral, Twice A Day (BID), 10 days
Drug: Apixaban
Also known as: BMS-562247
Pharmacokinetic (PK): Model-derived population & individual PK parameters (e.g., CL/F, Vc/F, KA) used to estimate steady state Cmax & AUC(TAU), Cmin & Tmax in each subject. Population PK model will be developed using plasma concentration vs time data
Time frame: Days 1, 2, Day 5, 6 or 7 and Day 11
Evidence of anti-Factor Xa confirmed by analysis of anti-Factor Xa PD analysis
Time frame: Days 1, 2, Day 5, 6 or 7
Ran from Jul 2011 to primary completion in Jun 2012, 10 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apixaban